Post-Conference Perspectives
January 03, 2019 –
Rafael Fonseca, MD, discusses the reimbursement status of the various treatment options for multiple myeloma.
January 03, 2019 –
Rafael Fonseca, MD, reviews the studies presented at ASH 2018—ARROW, OPTIMISMM, and ELOQUENT-3—and shares the outlook of therapy and unmet needs in myeloma.
December 26, 2018 –
Rafael Fonseca, MD, defines the clinical significance of minimal residual disease (MRD) testing and the approach to relapsed/refractory for myeloma.
December 26, 2018 –
Rafael Foseca, MD, reviews the NCCN guidelines for multiple myeloma and the transplant candidates VRD and KRD and discusses the CoMMpass trial.
